Tao Zhu
Founder chez CANSINO BIOLOGICS INC.
Profil
Tao Zhu is the founder of CanSino Biologics, Inc., which was founded in 2009.
He holds the title of Chief Scientific Officer at CanSino Biologics, Inc. from 2024 to the present.
Dr. Zhu is currently working as an Independent Director at Beijing Mabworks Biotech Co., Ltd.
since 2020.
Previously, he worked as a Senior Research Scientist at Sanofi from 2006 to 2009.
Dr. Zhu obtained a doctorate degree from Carnegie Mellon University in 2004 and a doctorate degree from the University of Pittsburgh in 2003.
He also received an undergraduate degree from Tsinghua University in 1995 and a graduate degree from Tsinghua University in 1998.
Postes actifs de Tao Zhu
| Sociétés | Poste | Début |
|---|---|---|
| CANSINO BIOLOGICS INC. | Founder | 13/01/2009 |
Beijing Mabworks Biotech Co., Ltd.
 Beijing Mabworks Biotech Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Mabworks Biotech Co., Ltd. engages in the discovery, development, manufacturing and commercialization of therapeutic antibodies. It develops antibody drugs and macromolecular biological drugs. The firm’s products include MIL60, MIL62, MIL86, MBS301, MIL77, and MIL93. The company was founded on February 27, 2003 and is headquartered in Beijing, China. | Director/Board Member | 26/03/2020 |
Anciens postes connus de Tao Zhu
| Sociétés | Poste | Fin |
|---|---|---|
| SANOFI | Corporate Officer/Principal | 01/01/2009 |
Formation de Tao Zhu
| Carnegie Mellon University | Doctorate Degree |
| University of Pittsburgh | Doctorate Degree |
| Tsinghua University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| SANOFI | Health Technology |
| CANSINO BIOLOGICS INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Beijing Mabworks Biotech Co., Ltd.
Beijing Mabworks Biotech Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Mabworks Biotech Co., Ltd. engages in the discovery, development, manufacturing and commercialization of therapeutic antibodies. It develops antibody drugs and macromolecular biological drugs. The firm’s products include MIL60, MIL62, MIL86, MBS301, MIL77, and MIL93. The company was founded on February 27, 2003 and is headquartered in Beijing, China. | Health Technology |
